These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 22244938)

  • 1. Discovery of GS-9256: a novel phosphinic acid derived inhibitor of the hepatitis C virus NS3/4A protease with potent clinical activity.
    Sheng XC; Casarez A; Cai R; Clarke MO; Chen X; Cho A; Delaney WE; Doerffler E; Ji M; Mertzman M; Pakdaman R; Pyun HJ; Rowe T; Wu Q; Xu J; Kim CU
    Bioorg Med Chem Lett; 2012 Feb; 22(3):1394-6. PubMed ID: 22244938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel, potent, and orally bioavailable phosphinic acid inhibitors of the hepatitis C virus NS3 protease.
    Clarke MO; Chen X; Cho A; Delaney WE; Doerffler E; Fardis M; Ji M; Mertzman M; Pakdaman R; Pyun HJ; Rowe T; Yang CY; Sheng XC; Kim CU
    Bioorg Med Chem Lett; 2011 Jun; 21(12):3568-72. PubMed ID: 21601450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical characterization of the novel HCV NS3 protease inhibitor GS-9256.
    Yang H; Yang C; Wang Y; Rhodes G; Robinson M; Cheng G; Qi X; Mo H; Tian Y; Pakdaman R; Sheng XC; Kim CU; Delaney WE
    Antivir Ther; 2017; 22(5):413-420. PubMed ID: 28106531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of GS-9451: an acid inhibitor of the hepatitis C virus NS3/4A protease.
    Sheng XC; Appleby T; Butler T; Cai R; Chen X; Cho A; Clarke MO; Cottell J; Delaney WE; Doerffler E; Link J; Ji M; Pakdaman R; Pyun HJ; Wu Q; Xu J; Kim CU
    Bioorg Med Chem Lett; 2012 Apr; 22(7):2629-34. PubMed ID: 22366653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of novel phosphonate derivatives as hepatitis C virus NS3 protease inhibitors.
    Sheng XC; Pyun HJ; Chaudhary K; Wang J; Doerffler E; Fleury M; McMurtrie D; Chen X; Delaney WE; Kim CU
    Bioorg Med Chem Lett; 2009 Jul; 19(13):3453-7. PubMed ID: 19477126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of novel P3-oxo inhibitor of hepatitis C virus NS3/4A serine protease.
    Duan M; Kazmierski W; Crosby R; Gartland M; Ji J; Tallant M; Wang A; Hamatake R; Wright L; Wu M; Zhang YK; Ding CZ; Li X; Liu Y; Zhang S; Zhou Y; Plattner JJ; Baker SJ
    Bioorg Med Chem Lett; 2012 Apr; 22(8):2993-6. PubMed ID: 22425454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection.
    Tsantrizos YS; Bolger G; Bonneau P; Cameron DR; Goudreau N; Kukolj G; LaPlante SR; Llinàs-Brunet M; Nar H; Lamarre D
    Angew Chem Int Ed Engl; 2003 Mar; 42(12):1356-60. PubMed ID: 12671967
    [No Abstract]   [Full Text] [Related]  

  • 8. Inhibitors of hepatitis C virus NS3/4A: alpha-ketoamide based macrocyclic inhibitors.
    Avolio S; Robertson K; Hernando JI; DiMuzio J; Summa V
    Bioorg Med Chem Lett; 2009 Apr; 19(8):2295-8. PubMed ID: 19285390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The design of a potent inhibitor of the hepatitis C virus NS3 protease: BILN 2061--from the NMR tube to the clinic.
    Tsantrizos YS
    Biopolymers; 2004; 76(4):309-23. PubMed ID: 15386268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery and structural diversity of the hepatitis C virus NS3/4A serine protease inhibitor series leading to clinical candidate IDX320.
    Parsy CC; Alexandre FR; Bidau V; Bonnaterre F; Brandt G; Caillet C; Cappelle S; Chaves D; Convard T; Derock M; Gloux D; Griffon Y; Lallos LB; Leroy F; Liuzzi M; Loi AG; Moulat L; Chiara M; Rahali H; Roques V; Rosinovsky E; Savin S; Seifer M; Standring D; Surleraux D
    Bioorg Med Chem Lett; 2015 Nov; 25(22):5427-36. PubMed ID: 26410074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel potent macrocyclic inhibitors of the hepatitis C virus NS3 protease: use of cyclopentane and cyclopentene P2-motifs.
    Bäck M; Johansson PO; Wångsell F; Thorstensson F; Kvarnström I; Ayesa S; Wähling H; Pelcman M; Jansson K; Lindström S; Wallberg H; Classon B; Rydergård C; Vrang L; Hamelink E; Hallberg A; Rosenquist S; Samuelsson B
    Bioorg Med Chem; 2007 Nov; 15(22):7184-202. PubMed ID: 17845856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350.
    Raboisson P; de Kock H; Rosenquist A; Nilsson M; Salvador-Oden L; Lin TI; Roue N; Ivanov V; Wähling H; Wickström K; Hamelink E; Edlund M; Vrang L; Vendeville S; Van de Vreken W; McGowan D; Tahri A; Hu L; Boutton C; Lenz O; Delouvroy F; Pille G; Surleraux D; Wigerinck P; Samuelsson B; Simmen K
    Bioorg Med Chem Lett; 2008 Sep; 18(17):4853-8. PubMed ID: 18678486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of potent macrocyclic inhibitors of genotype 3a HCV NS3/4A protease.
    Rudd MT; McCauley JA; Romano JJ; Butcher JW; Bush K; McIntyre CJ; Nguyen KT; Gilbert KF; Lyle TA; Holloway MK; Wan BL; Vacca JP; Summa V; Harper S; Rowley M; Carroll SS; Burlein C; DiMuzio JM; Gates A; Graham DJ; Huang Q; Ludmerer SW; McClain S; McHale C; Stahlhut M; Fandozzi C; Taylor A; Trainor N; Olsen DB; Liverton NJ
    Bioorg Med Chem Lett; 2012 Dec; 22(23):7201-6. PubMed ID: 23021993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blunting the Swiss army knife of hepatitis C virus: inhibitors of NS3/4A protease.
    White PW; Llinas-Brunet M; Bös M
    Prog Med Chem; 2006; 44():65-107. PubMed ID: 16697895
    [No Abstract]   [Full Text] [Related]  

  • 15. Novel 2-oxoimidazolidine-4-carboxylic acid derivatives as hepatitis C virus NS3-4A serine protease inhibitors: synthesis, activity, and X-ray crystal structure of an enzyme inhibitor complex.
    Arasappan A; Njoroge FG; Parekh TN; Yang X; Pichardo J; Butkiewicz N; Prongay A; Yao N; Girijavallabhan V
    Bioorg Med Chem Lett; 2004 Dec; 14(23):5751-5. PubMed ID: 15501035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a cell-based assay for monitoring hepatitis C virus ns3/4a protease activity.
    Lei YF; Yin W; Yang J; Lv X; Wei SH; An QX; Hu XB; Xu ZK
    Acta Virol; 2008; 52(3):133-41. PubMed ID: 18999887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel macrocyclic inhibitors of hepatitis C NS3/4A protease featuring a 2-amino-1,3-thiazole as a P4 carbamate replacement.
    Di Francesco ME; Dessole G; Nizi E; Pace P; Koch U; Fiore F; Pesci S; Di Muzio J; Monteagudo E; Rowley M; Summa V
    J Med Chem; 2009 Nov; 52(22):7014-28. PubMed ID: 19856919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and antiviral activity of HCV NS3/4A peptidomimetic boronic acid inhibitors.
    Boloor A; Hanway D; Joshi M; Winn DT; Mendez G; Walls M; Wei P; Qian F; Zhang X; Zhang Y; Hepperle ME; Li X; Campbell DA; Betancort JM
    Bioorg Med Chem Lett; 2009 Oct; 19(19):5708-11. PubMed ID: 19713109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A protease.
    Liverton NJ; Holloway MK; McCauley JA; Rudd MT; Butcher JW; Carroll SS; DiMuzio J; Fandozzi C; Gilbert KF; Mao SS; McIntyre CJ; Nguyen KT; Romano JJ; Stahlhut M; Wan BL; Olsen DB; Vacca JP
    J Am Chem Soc; 2008 Apr; 130(14):4607-9. PubMed ID: 18338894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphorous acid analogs of novel P2-P4 macrocycles as inhibitors of HCV-NS3 protease.
    Pompei M; Francesco ME; Koch U; Liverton NJ; Summa V
    Bioorg Med Chem Lett; 2009 May; 19(9):2574-8. PubMed ID: 19328685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.